EMEA anorectic withdrawals
Celltech and other phentermine manufacturers are considering European Court appeal of the EMEA decision to withdraw the diet drug, but have not done so yet. The company, along with other anorectic drug makers, made a formal appeal to EMEA to prevent withdrawal of the products due to an unfavorable risk/benefit profile, which was rejected (1"The Pink Sheet" April 17, p. 19)
You may also be interested in...
The European withdrawal of diethylproprion will be delayed on appeal as the EU moves to remove amphetamine-like diet drugs from the market.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials